Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HLX07 with chemotherapy or as monotherapy in EGFR-high advanced nonsquamous NSCLC
CTR20220506Phase 2Suspended
- Sponsor
- Henlius
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pimurutamab in non-small cell lung cancer (NSCLC), sponsored by Henlius. Started Mar 2022; status: suspended.
02
Drugs
pimurutamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20220506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220506.